FDA slaps a hold on Voyager's lead gene therapy over 'MRI abnormalities'
A rocky year for gene therapy is closing out with more bleak news.
Voyager Therapeutics announced Tuesday that the FDA has forced the company to halt studies on their lead program, a gene therapy for Parkinson’s disease, after “MRI abnormalities” appeared in some patients in a Phase II trial. The hold comes a month after Voyager disclosed that a data safety monitoring board had recommended a pause after “review[ing] certain patient imaging data.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.